MK-1026
Biological
Merck Sharp & Dohme Corporation
Total Payments
$1.4M
Transactions
29
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.4M | 29 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.4M | 29 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1,2 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies | Merck Sharp & Dohme Corporation | $1.4M | 0 |
Top Doctors Receiving Payments for MK-1026
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Salt Lake City, UT | $1.4M | 29 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $1.4M
- Total Doctors 0
- Transactions 29
About MK-1026
MK-1026 is a biological associated with $1.4M in payments to 0 healthcare providers, recorded across 29 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2020 to 2020. In 2020, $1.4M was paid across 29 transactions to 0 doctors.
The most common payment nature for MK-1026 is "Unspecified" ($1.4M, 100.0% of total).
MK-1026 is associated with 1 research study, including "A Phase 1,2 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies" ($1.4M).